Welcome to our dedicated page for Orthofix Med news (Ticker: OFIX), a resource for investors and traders seeking the latest updates and insights on Orthofix Med stock.
Orthofix Medical Inc. (NASDAQ: OFIX) is a global medical technology company headquartered in Lewisville, Texas, with a focus on musculoskeletal care. The Orthofix news stream highlights developments across its spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, including updates related to the 7D FLASH™ Navigation System.
Investors and healthcare professionals following Orthofix news can review regular earnings announcements, where the company reports net sales and segment performance for Bone Growth Therapies, Spinal Implants, Biologics and Enabling Technologies, Global Spine and Global Orthopedics. These releases often include commentary on trends in U.S. Spine Fixation, bone growth therapy performance, and the progress of its orthopedics business focused on limb reconstruction.
News coverage also features regulatory and product milestones, such as FDA 510(k) clearance and CE Mark for the TrueLok™ Elevate Transverse Bone Transport System and the global commercial launch of TrueLok Elevate. Orthofix uses these announcements to describe how TrueLok Elevate fits into its TrueLok family of multiplanar external fixators and supports limb preservation and diabetic wound-related treatment needs.
In addition, Orthofix issues releases about upcoming investor conference appearances and the timing of quarterly financial results and conference calls. For anyone tracking OFIX, this news page provides a centralized view of the company’s public communications on financial performance, product launches, regulatory clearances and investor events.
Orthofix Medical Inc. (NASDAQ:OFIX) has announced it will release its second quarter 2021 financial results on Friday, August 6, 2021, before the market opens. The company’s President, Jon Serbousek, and CFO, Doug Rice, will conduct a conference call at 8:30 a.m. ET to discuss the results. Interested parties can access the call by dialing specific numbers or through a webcast available on the company's investor relations website.
Orthofix Medical Inc. (NASDAQ:OFIX) has launched the fiberFUSE™ Strip, a new bone-graft solution for spinal procedures. This innovative product is composed entirely of natural bone and is designed for optimized application in cervical and lumbar surgeries. The fiberFUSE Strip enables cellular ingrowth and new bone formation due to its unique composition. The technology was developed to provide convenience and effectiveness for spine surgeons and their patients. MTF Biologics is the exclusive processor of this product, ensuring high-quality standards through validated aseptic processing.
Orthofix Medical Inc. (NASDAQ:OFIX) announced significant findings from a retrospective study published in The International Journal of Spine Surgery, highlighting a 92.7% fusion rate for patients undergoing three- and four-level lumbar arthrodesis surgery with the SpinalStim device. This data, gathered from 55 patients, reinforces the effectiveness of Pulsed Electromagnetic Field Stimulation (PEMF) therapy even among high-risk patients. The device is FDA-approved for lumbar spinal fusion procedures and is supported by the STIM onTrack mobile app, enhancing patient engagement in recovery.
Orthofix Medical Inc (NASDAQ: OFIX) has launched the FORZA Ti PLIF Spacer System in the U.S., designed for enhancing Posterior Lumbar Interbody Fusion (PLIF) procedures. The device is 3D-printed with optimized porosity and features to support bone ingrowth, critical for surgical success. Key features include a large graft window, titanium endplates with 400 micron pores, and a functional gradient porous structure. The FORZA Ti system is part of Orthofix's growing portfolio of innovative 3D-printed titanium products aimed at improving surgical outcomes.
Orthofix Medical, a global medical device company focused on spine and orthopedics, announced that CEO Jon Serbousek and CFO Doug Rice will participate in a fireside chat at the JMP Securities Life Sciences Conference on June 16, 2021, at 11:00 a.m. ET. The virtual event will include one-on-one meetings and a live audio webcast available on the Company’s website for interested stakeholders.
Orthofix aims to deliver innovative solutions to enhance patient mobility and distributes its products in over 60 countries.
Orthofix Medical Inc. (NASDAQ:OFIX) will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:30 p.m. ET. CEO Jon Serbousek and CFO Doug Rice will lead the discussion. The chat will be followed by one-on-one meetings. A live audio webcast can be accessed on the Company's website.
Orthofix specializes in innovative medical devices and biologics for spine and orthopedics, aiming to enhance patient mobility. Its products are distributed in over 70 countries from its headquarters in Lewisville, Texas.
Orthofix Medical Inc. (NASDAQ: OFIX) continues its sponsorship of Olympic Gold Medalist Laura Wilkinson as she trains for the Tokyo Olympics. Wilkinson, a three-time U.S. Olympic diver, overcame cervical disc degeneration with a successful spine fusion using Orthofix technology. At 39, she returned to diving, aiming to compete in the U.S. Olympic Team Trials from June 6-13, 2021. Orthofix's mission centers on improving patient mobility, and they express pride in supporting Wilkinson's journey while promoting awareness about spine health.
Orthofix Medical Inc. (NASDAQ:OFIX) has launched the OSCAR PRO Ultrasonic Arthroplasty Revision System in the U.S. and Europe. This advanced system aims to improve joint revision surgeries by effectively removing cement from failed implants, addressing challenges faced with traditional methods. As the fourth generation of the OSCAR line, it features an enhanced user interface and new data collection capabilities. The system is significant for the treatment of failed joint replacements, which may require surgical intervention due to cement adhesion.
Orthofix Medical Inc (NASDAQ:OFIX) announced positive preliminary results from the three- and four-year follow-up of its M6-C artificial cervical disc study. The data will be presented at the ISASS annual meeting on May 14. Key findings include a mean Neck Disability Index (NDI) score of 10.9 at three years and 10.3 at four years for M6-C patients, compared to 17.2 and 19.2 for the ACDF group, respectively. The study highlights statistically significant pain score improvements in neck and shoulder/arm pain. The M6-C disc, approved by the FDA in 2019, validates the benefits of cervical disc arthroplasty.
Orthofix Medical announced FDA 510(k) clearance for its OrthoNext digital platform, designed for deformity analysis and preoperative planning in pediatric orthopedic procedures. This platform complements the JuniOrtho Plating System, which targets advanced deformity and trauma reconstruction for pediatric patients. The company is progressing with a full market launch of the JuniOrtho system in the U.S. and Europe. This innovative combination aims to enhance surgical planning and optimize patient outcomes in pediatric orthopedic care.